Investigating a specific type of cancer linked to tuft cells
Official title: Biology and vulnerabilities of POU2F3+ tuft cell-like carcinomas
Funded at Cold Spring Harbor Laboratory · NIH-11080938 · Data updated 2026-11-12
This study is looking into a special kind of cancer called POU2F3+ tuft cell-like carcinoma to understand what makes it different from other cancers, with the hope of finding better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $673,208 |
| NIH project number | 5R01CA290004-02 |
| Project ID | NIH-11080938 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with POU2F3+ tuft cell-like carcinomas or related cancers.
✕Less likely to help
Patients with cancers that do not express POU2F3 or those with unrelated tumor types may not benefit from this research.
What this research studies
This research focuses on understanding a unique type of cancer known as POU2F3+ tuft cell-like carcinoma, which has been identified in various organs. The study aims to explore the biological mechanisms and molecular characteristics that differentiate these tumors from other cancer types. By examining the role of master regulator transcription factors, particularly POU2F3, the researchers hope to uncover new therapeutic strategies to target this cancer effectively. Patients may benefit from insights that could lead to more effective treatments tailored to this specific cancer lineage.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with tuft cell-like carcinomas.
How similar studies have gone: While the specific focus on POU2F3+ tuft cell-like carcinomas is relatively novel, targeting master regulators in cancer has shown promise in other studies.
Where this research is happening
-
Cold Spring Harbor Laboratory
Cold Spring Harbor, United States Active
Researchers
- Principal investigator: Vakoc, Christopher — Cold Spring Harbor Laboratory
- Study coordinator: Vakoc, Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.